Tickers

1. Composite Trajectory Verdict

Given Micron's capital-intensive, cyclical semiconductor manufacturing model, the income statement and cash flow statement carry the most weight for assessing financial performance, as they directly reflect the pricing-driven profitability and operational cash generation that fund its massive reinvestment cycle; the balance sheet is a derivative of those forces.

Composite Trajectory: Improving

The income statement shows a dramatic multi-year inflection from a FY2023 net loss of $5.8 billion to FY2025 net income of $8.5 billion, with Q3 FY2026 net income reaching $28.2 billion versus $1.9 billion in Q3 FY2025. Cash generation mirrors this trajectory, with operating cash flow rising from $1.6 billion in FY2023 to $17.5 billion in FY2025 and $45.7 billion in the first nine months of FY2026. The balance sheet has strengthened commensurately: cash and investments grew from $9.15 billion at FY2024 to $30.13 billion at Q3 FY2026 while total debt fell from $14.6 billion to $5.7 billion. No statement-level assessment contradicts this improving trend; all three show consistent, large-magnitude improvement across the comparable periods provided.

2. Red Flags

• Customer concentration: A single customer accounted for 17% of total revenue in FY2025 (primarily in CMBU) (10-K FY2025, Note 28).
• Sharp decline in customer prepayments: Prepayments and contract liabilities fell from $907 million at FY2024 to $169 million at FY2025, reducing a source of interest-free financing (10-K FY2025, Note 21).
• Rising effective tax rate due to Pillar Two: The nine-month FY2026 effective tax rate of 14.8% (vs. 11.5% in nine-month FY2025) reflects Singapore’s Pillar Two implementation largely offsetting prior tax incentives (10-Q Q3 FY2026, MD&A Income Taxes).
• Material litigation exposure: Multiple patent infringement suits (Netlist, YMTC, others) cover substantially all products; outcomes unpredictable but could result in significant liability or required product/process changes (10-K FY2025, Note 14).
• CHIPS Act clawback risk: Up to $6.4 billion in direct funding agreements contain clawback provisions for missed milestones, foreign-entity violations, or impermissible use (10-K FY2025, Note 20; Critical Audit Matter).
• Large near-term capital commitments: Purchase obligations for PP&E of $2.93 billion due within one year as of Q3 FY2026, with FY2026 net capex estimated at ~$27 billion (10-Q Q3 FY2026, Liquidity and Capital Resources).
• Debt prepayment losses: $59 million loss on debt prepayments in Q3 FY2026 nine months, including a $46 million loss on 2027 Notes swap settlement (10-Q Q3 FY2026, Note 24; 10-K FY2025, Note 12).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Revenue grew 49% YoY in FY2025 to $37.4 billion (10-K FY2025, Consolidated Statements of Operations) and surged 346% YoY in Q3 FY2026 to $41.5 billion (10-Q Q3 FY2026, Consolidated Statements of Operations). Gross margin expanded from -9% in FY2023 to 22% in FY2024 to 40% in FY2025 (10-K FY2025, Consolidated Statements of Operations), then to 85% in Q3 FY2026 (10-Q Q3 FY2026, Consolidated Statements of Operations). Operating income swung from a $5.7 billion loss in FY2023 to $9.8 billion in FY2025 (10-K FY2025, Consolidated Statements of Operations) and reached $33.3 billion in Q3 FY2026 versus $2.2 billion in Q3 FY2025 (10-Q Q3 FY2026, Consolidated Statements of Operations). Net income followed the same inflection: -$5.8 billion (FY2023), $778 million (FY2024), $8.5 billion (FY2025) (10-K FY2025, Consolidated Statements of Operations), and $28.2 billion in Q3 FY2026 vs. $1.9 billion in Q3 FY2025 (10-Q Q3 FY2026, Consolidated Statements of Operations). Diluted EPS rose from -$5.34 (FY2023) to $0.70 (FY2024) to $7.59 (FY2025) (10-K FY2025, Consolidated Statements of Operations). All segments posted large operating margin gains in Q3 FY2026 vs. Q3 FY2025 (10-Q Q3 FY2026, MD&A Operating Income by Business Unit).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Net cash from operating activities increased from $1.6 billion in FY2023 to $8.5 billion in FY2024 to $17.5 billion in FY2025 (10-K FY2025, Consolidated Statements of Cash Flows). In the first nine months of FY2026, operating cash flow reached $45.7 billion versus $11.8 billion in the comparable FY2025 period (10-Q Q3 FY2026, Consolidated Statements of Cash Flows). Investing outflows grew with capex: -$6.2 billion (FY2023), -$8.3 billion (FY2024), -$14.1 billion (FY2025) (10-K FY2025, Consolidated Statements of Cash Flows), and -$19.7 billion in nine-month FY2026 (10-Q Q3 FY2026, Consolidated Statements of Cash Flows), partially offset by government incentive proceeds ($2.0 billion in nine-month FY2026 vs. $1.3 billion in nine-month FY2025). Financing activities shifted from net inflows of $5.0 billion in FY2023 (debt issuance) to net outflows of -$1.8 billion in FY2024 and -$850 million in FY2025 (10-K FY2025, Consolidated Statements of Cash Flows), and -$10.6 billion in nine-month FY2026 driven by $9.4 billion of debt repayments and $650 million of share repurchases (10-Q Q3 FY2026, Consolidated Statements of Cash Flows). Cash and investments rose from $9.15 billion (FY2024) to $11.94 billion (FY2025) (10-K FY2025, Liquidity and Capital Resources) to $30.13 billion (Q3 FY2026) (10-Q Q3 FY2026, Liquidity and Capital Resources).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Total assets grew from $69.4 billion (FY2024) to $82.8 billion (FY2025) (10-K FY2025, Consolidated Balance Sheets) to $134.1 billion (Q3 FY2026) (10-Q Q3 FY2026, Consolidated Balance Sheets), driven by cash and receivables expansion. Cash and marketable investments increased from $9.15 billion (FY2024) to $11.94 billion (FY2025) (10-K FY2025, Liquidity and Capital Resources) to $30.13 billion (Q3 FY2026) (10-Q Q3 FY2026, Liquidity and Capital Resources). Total debt declined from $14.6 billion (FY2024) to $14.6 billion (FY2025) (10-K FY2025, Note 12) then sharply to $5.7 billion (Q3 FY2026) (10-Q Q3 FY2026, Consolidated Balance Sheets) after $9.4 billion of prepayments in nine-month FY2026 (10-Q Q3 FY2026, Consolidated Statements of Cash Flows). Shareholders’ equity rose from $45.1 billion (FY2024) to $54.2 billion (FY2025) (10-K FY2025, Consolidated Balance Sheets) to $100.7 billion (Q3 FY2026) (10-Q Q3 FY2026, Consolidated Balance Sheets), reflecting retained earnings accumulation of $8.5 billion in FY2025 and $47.3 billion in nine-month FY2026 (10-K FY2025, Consolidated Statements of Changes in Equity; 10-Q Q3 FY2026, Consolidated Statements of Changes in Equity). Inventories were roughly flat at $8.4–8.9 billion across periods (10-K FY2025, Consolidated Balance Sheets; 10-Q Q3 FY2026, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly YoY comparisons for Q1 and Q2 FY2026 (vs. Q1/Q2 FY2025) — not provided in the filings supplied.
• Stand-alone Q4 FY2025 results — only full-year FY2025 is available; cannot isolate Q4 trends.
• Segment-level quarterly revenue and operating income for Q1/Q2 FY2026 and Q1/Q2/Q4 FY2025 — only Q3 FY2026 and Q3 FY2025 segment data are disclosed.
• Free cash flow (operating cash flow minus capex) for annual FY2023–FY2025 — capex and operating cash flow are provided but not netted in the filings.
• Detailed debt maturity schedule beyond FY2026 — Note 12 in 10-K FY2025 shows maturities only through FY2031 and thereafter in aggregate.
• Quantitative impact of OBBBA tax changes — disclosed as uncertain; no dollar estimate provided (10-K FY2025, Note 25; 10-Q Q3 FY2026, MD&A Income Taxes).
• Resolution timeline and potential loss range for major patent litigations (Netlist, YMTC) — explicitly stated as not reasonably estimable (10-K FY2025, Note 14).